Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for hard-to-treat lung cancer: targeted drugs before surgery

NCT ID NCT06563999

First seen May 01, 2026 · Last updated Jun 13, 2026 · Updated 7 times

Summary

This study tests whether giving targeted drugs before surgery can help people with stage III lung cancer that has rare gene changes. About 120 adults who have not had treatment will receive a drug matched to their tumor's mutation, then doctors will check if the tumor becomes removable. The goal is to see if this approach can shrink tumors enough for surgery and improve long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER STAGE III are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.